PAMA brings huge changes to lab price testing, faces resistance from ACLA

PAMA brings huge changes to lab price testing, faces resistance from ACLA

The Protecting Access to Medicare Act (PAMA) of 2014 has surprised the industry with sweeping, potentially devastating cuts to how lab tests are reimbursed through Medicare, with a whole host of tests seeing cuts of over a third. The American Clinical Laboratory Association (ACLA) is fighting back with a lawsuit over the methodology of the Centers for Medicare and Medicaid’s (CMS) data collection in determining the new pricing scheme. The American Association for Clinical Chemistry (AACC) also weighs in, and asserts that labs will need to make some big changes if they want to survive.


Hospital & Independent Lab Testing in the Clinical Testing Market

Hospital & Independent Lab Testing in the Clinical Testing Market

The interplay or competitive balance between independent laboratories and hospital labs in the United States merits attention in the coming years as the future of clinical testing will be overwhelmingly shaped in the two segments. After seeing business contract by nearly 5% over the past five years , independent labs are projected by Kalorama Information to realize new growth in an altered U.S. healthcare landscape. The Affordable Care Act (ACA) will create opportunities to expand for all labs, ...